Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and Management of Chronic Kidney Disease-Mineral Bone Disease in Children

  • Suh, Jin-Soon (Department of Pediatrics, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2020.03.11
  • Accepted : 2020.04.24
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic kidney disease-mineral bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism caused by CKD. Patients with early-stage CKD who present with disordered regulation of bone and mineral metabolism may be asymptomatic. However, if untreated, the condition can be a significant barrier in achieving optimal bone strength, linear growth, and cardiovascular health in pediatric patients with CKD. Thus, the current study evaluated the definition, pathogenesis, diagnosis, and management of pediatric CKD-MBD.

Keywords

References

  1. Andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int 2013;84:622-3. https://doi.org/10.1038/ki.2013.243
  2. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003;111(6 Pt 1):1416-21. https://doi.org/10.1542/peds.111.6.1416
  3. Hanudel MR, Salusky IB. Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Curr Osteoporos Rep 2017;15:198-206. https://doi.org/10.1007/s11914-017-0365-0
  4. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 2008;23:195-207. https://doi.org/10.1007/s00467-007-0671-3
  5. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-8. https://doi.org/10.1038/ki.2011.47
  6. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;280:2543-9. https://doi.org/10.1074/jbc.M408903200
  7. Portale AA, Booth BE, Halloran BP, Morris RC, Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580-9. https://doi.org/10.1172/JCI111365
  8. Naveh-Many T, Silver J. The Pas de Trois of Vitamin D, FGF23, and PTH. J Am Soc Nephrol 2017;28:393-5. https://doi.org/10.1681/ASN.2016090944
  9. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83. https://doi.org/10.1056/NEJM200005183422003
  10. Kidney Disease: Improving Global Outcomes CKDMBDUWG. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 2017;7:1-59. https://doi.org/10.1016/j.kisu.2017.04.001
  11. Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000;89:666-71. https://doi.org/10.1111/j.1651-2227.2000.tb00361.x
  12. Haffner D, Leifheit-Nestler M. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels. Pediatr Nephrol 2020;35:485-91. https://doi.org/10.1007/s00467-019-04399-0
  13. Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol 2019;34:475-86. https://doi.org/10.1007/s00467-018-4116-y
  14. Haffner D, Leifheit-Nestler M. Extrarenal effects of FGF23. Pediatr Nephrol 2017;32:753-65. https://doi.org/10.1007/s00467-016-3505-3
  15. Bacchetta J. Treatment of hyperphosphatemia: the dangers of high PTH levels. Pediatr Nephrol 2020;35:493-500. https://doi.org/10.1007/s00467-019-04400-w
  16. McAlister L, Pugh P, Greenbaum L, Haffner D, Rees L, Anderson C, et al. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2020;35:501-18. https://doi.org/10.1007/s00467-019-04370-z
  17. Fathallah-Shaykh S, Drozdz D, Flynn J, Jenkins R, Wesseling-Perry K, Swartz SJ, et al. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease. Pediatr Nephrol 2018;33:325-33. https://doi.org/10.1007/s00467-017-3787-0
  18. Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012;7:216-23. https://doi.org/10.2215/CJN.04760511
  19. Group KW. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis 2009;53(3 Suppl 2):S11-104.
  20. Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987;9:206-10. https://doi.org/10.1016/s0272-6386(87)80056-2
  21. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003;18:1260-4. https://doi.org/10.1007/s00467-003-1298-7
  22. Habbous S, Przech S, Acedillo R, Sarma S, Garg AX, Martin J. The efficacy and safety of sevelamer and lanthanum versus calciumcontaining and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2017;32:111-25.
  23. Sekercioglu N, Thabane L, Diaz Martinez JP, Nesrallah G, Longo CJ, Busse JW, et al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One 2016;11:e0156891. https://doi.org/10.1371/journal.pone.0156891
  24. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel ironbased phosphate binder in dialysis patients. Kidney Int 2014;86:638-47. https://doi.org/10.1038/ki.2014.58
  25. Hanudel MR, Laster M, Ramos G, Gales B, Salusky IB. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients. Pediatr Nephrol 2018;33:2137-42. https://doi.org/10.1007/s00467-018-3999-y
  26. Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984;310:1079-84. https://doi.org/10.1056/NEJM198404263101704
  27. Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014;9:344-53. https://doi.org/10.2215/CJN.05840513
  28. Shroff R, Wan M, Nagler EV, Bakkaloglu S, Fischer DC, Bishop N, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant 2017;32:1098-113. https://doi.org/10.1093/ndt/gfx065
  29. Shroff R, Wan M, Nagler EV, Bakkaloglu S, Cozzolino M, Bacchetta J, et al. Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant 2017;32:1114-27. https://doi.org/10.1093/ndt/gfx080
  30. Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94. https://doi.org/10.1056/NEJMoa1205624
  31. Joseph C, Shah S, Geer J, Juarez-Calderon M, Srivaths PR, Swartz SJ. Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years. Clin Nephrol 2019;92:279-86. https://doi.org/10.5414/CN109871